Table 4.

Sensitivity Analyses: Hazard Ratio of Incident Diabetes

Characteristics	Psoriasis Overall	Mild Psoriasis	Severe Psoriasis
Original Model*	1.14 (1.10–1.18)	1.11 (1.07, 1.15)	1.46 (1.30, 1.65)
Restricting to patients who were seen at least once a year: HR Incident Diabetes* (95% CI)	1.13 (1.09–1.72)	1.10 (1.06–1.15)	1.46 (1.28, 1.65)
Excluding patients with psoriatic arthritis: HR Incident Diabetes* (95% CI)	1.13 (1.09, 1.17)	1.11 (1.07, 1.15)	1.50 (1.29, 1.74)
Excluding patients who ever received a systemic steroid, retinoid or cyclosporine: HR Incident Diabetes* (95% CI)	1.12 (1.07, 1.17)	1.11 (1.06, 1.16)	1.44 (1.21, 1.72)
Restricting to patients who received an oral retinoid or phototherapy: HR Incident Diabetes* (95% CI)	NA	NA	1.52 (1.20, 1.93)
Restricting to patients with a diabetes diagnosis that occurs at least one year after the start date: HR Incident Diabetes* (95% CI)	1.14 (1.10, 1.19)	1.11 (1.07, 1.16)	1.45 (1.27, 1.65)
Restricting to patients who were seen prior to 2005, i.e., prior to when biologic therapy becoming prevalent for psoriasis treatment in the UK: HR Incident Diabetes* (95% CI)	NA	NA	1.54 (1.30–1.83)
Restricting to patients who were at least 50 years old: HR Incident Diabetes* (95% CI)	1.15 (1.10–1.20)	1.13 (1.08–1.76)	1.42 (1.23–1.64)

^*adjusted for age, sex, BMI, hypertension, hyperlipidemia